Specifically, Musa et al. found that EwS patients with elevated expression of the oncogenic transcription factor, MYBL2, have poor overall survival and that high MYBL2 levels sensitize tumor cells to anti-CDK2 therapy [213]. This evidence concerns the gene MYBL2 and neoplasm.